Hikal Ltd Q4 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/rfptttz22asyum3cq07ahxo3.pdf

Key Takeaways


The FDA Overhang: Bangalore Warning Letter

Hiremath: "We are going through this bit of an aberration, a dip. I think it's now getting behind us. In the next few quarters, we'll be out of it. And the visibility for medium to long-term revenue growth still stands."

Pharma & CDMO: The Growth Engine Under Repair


Crop Protection: A Cycle Turning

Hiremath: "We believe the industry has now largely moved beyond the worst phase of the cycle."

Animal Health & Diversification


Margins & Cost Headwinds

Hiremath: "net-net, we will end up ensuring that there's no significant impact on the bottom line, although for 1 or 2 quarters, especially quarter 1, there could be some marginal impact because by the time the pass-through happens and the negotiations end, there's a lag effect."

Guidance & Commitments

CommitmentSpecificsTimeline
FDA resolutionInspection expected, all CAPAs nearing completionEnd of this year
DMF filing cadence5 to 6 filings annually (up from 2–3 historically)Ongoing from FY27
HPAPI manufacturing facilityPlanned in PuneOver FY28
HPAPI/ADC revenue scale-upMeaningful scale-up3 to 5 years
Animal Health revenue targetINR500 crores plusNext 4–5 years
Crop Protection NCE launchesNew products from RFPs won in the last yearFY27
Brazil officeEstablishment in progressNot specified
FY27 margin outlookSustain at improved levels, supported by demand visibility and operating leverageFY27
Raw material pass-throughCustomer-supported mechanisms to partially offset cost increases; marginal Q1 impact possibleQ1 FY27 lag, then normalize
FY30 strategic planPlans stand but delayed by 2–3 years due to recent setbacksFY32–33 (implied)

Key Metrics

MetricQ4 FY26
Revenue₹519 cr, FY26 revenue ₹1,713 cr
EBITDA₹105 cr, EBITDA margin 20.3%
EBITDA margin20.3%, improved over previous quarter; FY26 margin 12.9%
PAT₹14.4 cr, after exceptional item of ₹47 cr for Panoli plant impairment
Pharma revenue₹292 cr, FY26 revenue ₹1,021 cr
Pharma EBIT margin12%, EBIT ₹35 cr; sequential operating profit up 45%
Crop Protection revenue₹228 cr, FY26 revenue ₹692 cr
Crop Protection EBIT margin17.1%, EBIT ₹39 cr
Pharma capacity utilization80% to 85%, at Panoli and Bangalore plants, up from 75% last year
DMF filings target5 to 6 annually, compared to 2 to 3 historically
FY26 capex₹149 cr, for debottlenecking, regulatory upgrades, expanding CDMO capacities
Debt-to-equity ratio0.56, reduced from 0.59 as on March 31, 2026
FY26 adjusted PBT from operations₹7 cr, after adjusting exceptional items of ₹85 cr
Animal Health medium-term revenue target₹500 cr plus, in next 4 to 5 years, on track per September guidance